Clinical Trial Update: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer [Phase 2]

View source ↗

Summary

Phase II trial of the CDK inhibitor PD 0332991 (palbociclib) in various adult solid tumors including colon and breast cancers has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Colon
• Adenocarcinoma of the Rectum
• Breast Cancer
• Colon Cancer
• Colorectal Cancer
• Estrogen Receptor Negative Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Extragonadal Germ Cell Tumor
• Extragonadal Non-seminomatous Germ Cell Tumor
• Extragonadal Seminoma
• Male Breast Cancer
• Malignant Testicular Germ Cell Tumor
• Melanoma
• Ovarian Germ Cell Tumor
• Ovarian Immature Teratoma
• Ovarian Mature Teratoma
• Rectal Cancer

Drugs mentioned

• PD 0332991 (palbociclib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon | Phase 2 | Status: COMPLETED | Results posted: 2021-03-11